You are here: Industry Insights > anaemia

News List

NICE publish final guidance recommending Aspaveli in adults with ultra-rare blood disorder PharmaTimes
December 10, 2021
The drug is additionally undergoing assessment with the Medicines and Healthcare products Regulatory Agency for a marketing authorisation in the UK.
US rejects AZ and FibroGen’s anaemia drug roxadustat pharmatimes
August 13, 2021
The US Food and Drug Administration (US) has handed AstraZeneca a complete response letter (CRL) regarding its anaemia drug roxadustat.
Japan grants approval for GSK’s Duvroq to treat CKD-related anaemia pharmaceutical-technology
June 30, 2020
Japan’s Ministry of Health, Labour and Welfare has granted the first regulatory approval for GlaxoSmithKline (GSK)’s Duvroq (daprodustat) to treat anaemia caused by chronic kidney disease (CKD).
EC clears new class of anaemia therapy pharmatimes
June 29, 2020
The European Commission has approved BMS’ blood disease therapy Reblozyl (luspatercept) for the treatment of transfusion-dependent anaemia associated with myelodysplastic syndromes (MDS) or beta thalassaemia.
Treatment for dialysis patients with CKD anaemia approved in Japan europeanpharmaceuticalreview
September 23, 2019
A treatment for anaemia associated with chronic kidney disease in dialysis patients has been approved in Japan.
China approves AstraZeneca drug to treat anaemia in CKD patients biospectrumasia
August 25, 2019
China becomes the first country to approve roxadustat for all chronic kidney disease (CKD) patients with anaemia
AstraZeneca’s roxadustat reveals positive results against anaemia biospectrumasia
July 28, 2019
AstraZeneca and FibroGen China, a wholly-owned subsidiary of FibroGen Inc., are collaborating on the development and commercialisation of roxadustat in China
Astellas’ kidney disease drug shows promise in PhIII pharmatimes
September 27, 2018
A Phase III study assessing Astellas’ roxadustat in patients with chronic kidney disease (CKD) and anaemia who are not receiving dialysis has met its key endpoints.
Zydus starts phase II trial of ZYAN1 for treating anaemia in patients with CKD financialexpress
July 06, 2017
ZYAN1 has been shown to improve iron mobilisation and has the potential to reduce or eliminate the need for iron supplementation
Zydus starts phase II trial of ZYAN1 for treating anaemia in patients with CKD expressbpd
July 06, 2017
ZYAN1 has been shown to improve iron mobilisation and has the potential to reduce or eliminate the need for iron supplementation

Previous page 1 2 Next page